What if health systems provided rides for elderly patients with limited transportation options or poor patients unable to access public transportation? We might applaud them for a creative strategy to improve access for vulnerable populations. However, their actions might be illegal. We navigated these legal challenges as we designed a rideshare-based medical transportation service using Lyft to help Medicaid patients get to their primary care appointment.
A new study points to nursing as a key to achieving value in health care. The researchers ask whether investing in an intervention aimed at supporting direct care nurses – Magnet recognition – influences hospitals’ performance on Medicare’s Hospital Value Based Purchasing (VBP) measures. Indeed, Magnet recognition is associated with better performance on VBP measures.
Penn’s third annual Martin Luther King Health Equity Symposium featured a keynote address by Antonia Novello, 14th Surgeon General of the United States, who had a hopeful, yet challenging message: “Had Martin Luther King been here today, he would see that we are doing much better, but he would he would still be fighting. He would feel pride, disappointment, sadness, and he would be appalled that blacks and whites are still segregated.”
A new study finds that the reformulated, abuse-deterrent version of OxyContin led to short-term substitution toward heroin. The overall effectiveness of abuse-deterrent formulations will become more evident over time as we observe whether reductions in new initiation eventually offset short-term substitution to heroin.
New policies and technologies can empower pediatric clinicians and pediatric health care systems to help parent smokers quit. Fortunately, new policies outside of the health care setting may help prevent smoking initiation, as well as improve cessation treatments. [This blog originally appeared on the PolicyLab at Children’s Hospital of Philadelphia blog. View the original blog post here.]
Our colleagues at the Wharton Public Policy Initiative have released a new Issue Brief, The Economic Realities of Replacing the Affordable Care Act, by LDI Senior Fellow Hanming Fang, PhD. In it, Fang uses new a new model of labor and health insurance market dynamics to simulate the long-run effects of the ACA's mechanisms, thus shedding some much-needed light on the repeal-and-replace debate.
Mental health care has taken a back seat in the never-ending debate on health care reform. For individuals with psychiatric and developmental disabilities, aspects of the AHCA place their “future in jeopardy.”
We don’t yet know exactly how the bill would affect the number of people covered and the cost to the government. However, early impressions of the bill suggest fewer people will be covered. Many lower-wage workers would be priced out of health insurance entirely. Young and healthy people and those earning more money would be better off. However, older and lower-income individuals will generally be worse off. And every year that passes, consumers will be getting less help relative to the cost of health insurance.
March 9, 2017 [This post originally appeared on the PolicyLab at Children’s Hospital of Philadelphia blog.]
Current proposals to simultaneously repeal the Affordable Care Act (ACA) and reform the federal Medicaid program would be devastating to children and young adults with disabilities and complex medical needs.
Despite making national headlines only relatively recently, the opioid problem been building for years and will take years to address. Tough questions must be asked and answered. Here's what the Philadelphia Department of Public Health is doing, and some of the questions needing study.
“Pay more for drugs that do more.” Although few would argue with the concept of paying for value, the mechanism for doing so has thus far eluded our multi-payer, market-based system. The Gant Precision Cancer Medicine Consortium at the University of Pennsylvania looked past US borders to learn about mechanisms in other countries, in its quest to recommend sustainable frameworks for valuing precision cancer drugs.